Amylyx Pharmaceuticals
Quarterly Financials
| Values in thousands | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 |
|---|---|---|---|---|
Revenue | $-1,022 | $88,643 | $108,449 | $102,693 |
Gross Profit | -8,648 | -28,078 | 99,089 | 97,475 |
EBITDA | -53,227 | -121,815 | 2,235 | 19,022 |
EBIT | -53,435 | -122,130 | 1,934 | 18,720 |
Net Income | -72,700 | -118,793 | 4,731 | 20,893 |
Net Change In Cash | -1,022 | 88,643 | 108,449 | 102,693 |
Free Cash Flow | -66,669 | -556 | 13,195 | -5,526 |
Cash | 74,999 | 170,552 | 170,201 | 135,258 |
Basic Shares | 68,024 | 67,854 | 69,196 | 69,748 |
Annual Financials
| Values in thousands | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
Revenue | $380,786 | $22,230 | $285 | $650 |
Gross Profit | 355,345 | 19,237 | 285 | -23,944 |
EBITDA | 39,890 | -200,854 | -82,636 | -38,721 |
EBIT | 38,802 | -201,341 | -82,688 | -38,722 |
Net Income | 49,271 | -198,375 | -87,879 | -44,837 |
Net Change In Cash | 380,786 | 22,230 | 285 | 650 |
Cost of Revenue | 12,930 | |||
Free Cash Flow | 10,678 | -182,397 | -75,152 | -36,848 |
Cash | 170,201 | 62,526 | 50,191 | 12,877 |
Basic Shares | 69,991 | 66,512 | 57,864 | 56,466 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-06-30 | -$0.73 |
2024-03-31 | -$0.12 |
2023-12-31 | $0.07 |
2023-09-30 | $0.30 |
